Genentech Takes Slice Of Novartis' Fovista Rights
This article was originally published in Scrip
Executive Summary
Roche's Genentech subsidiary is to join Novartis in another wet AMD adventure, having decided to exercise its option on Novartis' ex-US rights to Ophthotech Corporation's leading investigational PDGF inhibitor Fovista (pegpleranib).